



**Vaccine Innovation & Therapeutics
Acceleration Launchpad**

A BARDA Accelerator Network Hub

www.vitalhubhealth.com



Operated by

Start2[®]

ACI ADVISE
CONNECT
INSPIRE

biolabs



BARDA

The [Biomedical Advanced Research and Development Authority \(BARDA\)](#) supports the development of medical countermeasures – technologies and products to prevent, prepare for, and respond to health security threats including chemical, biological, radiological, and nuclear threats, pandemic influenza, and emerging infectious diseases. BARDA is part of Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS).

BARDA Accelerator Network (BAN)

The BARDA Accelerator Network fosters the growth of the global health security innovation ecosystem. The Network accelerates the development and commercialization of next-generation health security solutions. For more information, visit: drive.hhs.gov.

The network supports early-stage companies globally throughout their journey to help them overcome their biggest business, marketing, and operational hurdles, and achieve success sooner.





The BARDA Accelerator Network hub supporting development and acceleration of next generation therapeutic and vaccine platforms and technologies

A consortium of 3 companies, led by Start2

The logo for Start2, consisting of the word "Start2" in a bold, black, sans-serif font with a registered trademark symbol.

- Global startup accelerator since 2015
- Specific focus on biotech & healthtech
- start2.group


The logo for ACI, featuring the letters "ACI" in a large, blue, sans-serif font, followed by the words "ADVISE", "CONNECT", and "INSPIRE" stacked vertically in a smaller, grey, sans-serif font.

- Global startup accelerator since 2017
- Specific focus on biotech & healthtech
- aci-lifesciences.com

The logo for biolabs, featuring a stylized green and blue circular icon to the left of the word "biolabs" in a grey, sans-serif font.


- Innovation platform founded 2006
- Coworking laboratory facilities & support programs - 15 locations in US, EU, USA
- biolabs.io

VITAL Provides An Accelerator Program And Funding Awards



Biotech Accelerator Program


- Deep mentoring with subject matter experts for 6-months – clinical studies, regulatory, fundraising, BD, development, advisors
- Customer discovery and interactions with investors, partners




Funding Awards for Development, Evaluation, and Validation

- Non-dilutive, milestone-based funding for 6-month long projects
- Funding for development, evaluation, and validation of vaccine and therapeutic technologies and platforms

Biotech Accelerator Program



- Highly individualized mentor engagements with regular weekly meetings tailored to needs of each company
- Hybrid format, free of charge, no funds provided, and no equity taken



- Lead mentor and project manager for each company
- Extended mentor team of subject matter experts
- Deep Dive kickoff, SMART goals, custom workstreams



- Access to 250+ biotech & healthtech mentors – entrepreneurs, development experts, investors, clinicians
- Access to BioLabs' network programming & workshops

Accelerator Program Results

130+

Accelerator Program Alumni

13 Exits

\$2B+ Value

\$1.5B+

Follow-on Funding

550+

Supported in Co-working Labs

Selected Exits:



Acquired by Zambon
(2019)



Acquired by BioNTech
(2021)



Acquired by Exact Sciences
(2022)

Non-Dilutive Funding Awards

Milestone-based, Non-Dilutive Funding Awards
from \$50K to \$200K for 6-Month Long Projects



of therapeutic and vaccine technologies and platforms
aligned with BARDA's mission to enhance pandemic
preparedness and health security



- Project management support over award duration (9-months max)
- Periodic mentoring from subject matter experts in biotech development, validation, and fundraising

Accelerator & Funding Award Solicitations



- **Eligibility:** Accepting applications from academic projects and innovators, and early-stage biotech companies
- **Targeting:** Innovations vaccine and therapeutic technologies and platforms aligned with BARDA's mission *
- **Submission deadline:** August 23rd, 2024
- **Notification of awards:** By September 30th, 2024
- **Program start:** In mid-October 2024

* For more information on BARDA areas of interest, please visit <https://drive.hhs.gov/partner.html>. BARDA also recently released TPPs relevant to some of its areas of interest: <https://medicalcountermeasures.gov/barda/tpp>.

BARDA primarily develops medical countermeasures to counter acute threats and does not support research and development or acceleration in the areas of oncology or chronic disease. However, BARDA does partner with innovators and companies developing platform and multi-use technologies. Applicants can include data from other use cases so long as BARDA funding will be used to support research and development of the BARDA-relevant use cases.

BARDA funding can be used to demonstrate proof-of-concept for a BARDA-relevant use of an existing platform technology, or a high risk breakthrough technology or platform, or to advance technologies currently in development.